View the latest clinical trials, studies, data, and updates.
Ideal Medical Technologies intends to complete the first in man safety study by the end of 2022 and initiate the next safety study in ICU patients in Q1 2023. IMT is planning to bring the FUSION system to the hospital market in mid 2024.
Dr. Xiaofeng Zhang operated the robot outside the operating room (without wearing heavy lead), advanced the guidewire and balloon catheter in a precisely controlled manner and successfully completed the entire surgical procedure including the nipple cutter action, balloon stone removal, and accurate placement of bile duct stents.
The study represents the largest prospective “real world” evidence supporting the treatment of complex, heavily calcified peripheral arterial disease (PAD) with IVL. The final analysis was presented earlier today at VIVA22 in a late-breaking clinical trial session.
The DEEPER REVEAL IDE Clinical Study is a prospective, single-arm, multicenter study that will examine the efficacy and safety of the Spur Stent for the treatment of vascular lesions in patients with critical limb ischemia
This surgery marks a key milestone for Envoy Medical on the road toward bringing the Acclaim Cochlear Implant to market. If approved by the FDA, the Acclaim would be the first-of-its-kind cochlear implant designed to be fully implanted and use the ear, rather than a microphone, to pick up sound.
TechsoMed notes with its algorithm powered technology, the BioTraceIO software system is the first to provide visualization of the ablated area based on standard real-time ultrasound imaging intended to support interventional radiologists performing tumor ablation with valuable procedure outcomes assessment.